Specialty Pharmacy

This study points to the potential for using CAR T-cell therapy effectively against solid tumors, as well, according to the authors.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.

The FDA has granted a fast track designation to an investigational antibody-drug conjugate for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer.

Reports indicate a mortality rate of up to 28% among solid organ transplant patients hospitalized with coronavirus disease 2019.

The biologics license application lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA.

Consumption of sugary drinks regularly may be a major contributory factor to the epidemic of cancer, according to a study published by the British Medical Journal.

The research team designed TETi76 to replicate and amplify the effects of a natural molecule called 2-hydroxyglutarate (2HG), which inhibits the enzymatic activity of TET genes.

Randall A. Oyer, MD, discusses rising cancer mortality during the coronavirus disease 2019 (COVID-19) pandemic and what that means for cancer care.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the disease impact on the gynecologic system and how often patients become infertile due to this impact.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, details the treatment options available for patients with congenital plasminogen deficiency.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, describes common manifestations of congenital plasminogen deficiency and their impact on patient outcomes.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.

Anakinra was initially approved by FDA in November 2001 for treatment of moderate to severe active rheumatoid arthritis.

Without coordinated care to ensure proper adherence, the resulting costs can become downright staggering for health systems.

FDA approves margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens.

CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma.

The FDA has granted a fast track designation to devimistat (CPI-613) for the treatment of patients with acute myeloid leukemia.

Financial toxicity can lead to worse long-term outcomes and psychological distress among patients with breast cancer.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Study shows the mortality rate among breast cancer survivors is lower among those who received fertility preservation.

The cost of oncology treatment is high and rising in the United States.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.

The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.

Supreme Court decision establishes that states do have the right to regulate pharmacy benefit managers in managed care organizations.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.

MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.

Trials confirm patients with chronic lymphocytic leukemia treated with venetoclax-based regimens achieve higher rates of undetectable minimal residual disease, which may be associated with a lower risk of future disease progression or death.

An icatibant injection has been released in the United States as an alternative treatment for acute attacks of hereditary angioedema in adults over the age of 18 years.